Shots:
UCB has entered into a definitive agreement to acquire Neurona Therapeutics for up to $1.15B, including $650M upfront and up to $500M in potential milestones expected to close by end of Q2’26
The acquisition adds NRTX-1001, an investigational neuronal cell therapy currently in P-I/II study for drug-resistant mesial temporal lobe epilepsy, strengthening UCB’s neuroscience…
